

Medication-Assisted Treatment at Treatment Trends

Treatment Trends clients with Opioid Use Disorder may be deemed clinically and medically appropriate to participate in Medication-Assisted Treatment (MAT) utilizing extended release naltrexone (commonly known by its brand name VIVITROL®). The use of oral naltrexone or VIVITROL, supported by counseling, is voluntary. VIVITROL is the only MAT provided at Treatment Trends.

Information about MAT is provided to Treatment Trends clients. Education about VIVITROL includes discussion about its side effects and the heightened risk of overdose if clients attempt to override it by using heroin or opioids. A physician administers all doses of VIVITROL and monitors clients' progress in partnership with care managers with the Treatment Trends Center of Excellence and the client's counselor.

VIVITROL is an antagonist (it is a blocker and not an opiate replacement). A person cannot become addicted to VIVITROL and must complete detox prior to beginning treatment with VIVITROL.

VIVITROL is a monthly intramuscular injection that attaches to the opioid receptors in the brain and prevents the release of dopamine. VIVITROL creates a barrier that blocks opioid molecules from attaching to opioid receptors. It is an added tool to counseling that helps to control cravings to prevent relapse into opioid dependence.

When a client is discharged from treatment at Keenan House, the Halfway Home of the Lehigh Valley, or Confront and is still receiving MAT with VIVITROL, the care managers at Treatment Trends Center of Excellence will assist to identify where clients may continue VIVITROL as part of their aftercare.

Clients interested in MAT that is not provided at Treatment Trends have the option to discuss alternatives during their aftercare planning. Referral to alternative MAT will be provided in compliance with the client's legal status.